Genomic Health, Inc. (NASDAQ:GHDX) CEO Kimberly J. Popovits sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $31.50, for a total transaction of $630,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Genomic Health, Inc. (NASDAQ:GHDX) opened at $36.13 on Thursday. Genomic Health, Inc. has a 1 year low of $26.37 and a 1 year high of $37.50.

Several institutional investors and hedge funds have recently made changes to their positions in GHDX. Vanguard Group Inc. grew its position in shares of Genomic Health by 6.8% during the second quarter. Vanguard Group Inc. now owns 1,670,622 shares of the medical research company’s stock worth $54,379,000 after acquiring an additional 106,452 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Genomic Health by 10.9% during the second quarter. Renaissance Technologies LLC now owns 813,300 shares of the medical research company’s stock worth $26,473,000 after acquiring an additional 80,100 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Genomic Health by 26.1% during the second quarter. Goldman Sachs Group Inc. now owns 370,806 shares of the medical research company’s stock worth $12,070,000 after acquiring an additional 76,758 shares during the last quarter. Citadel Advisors LLC grew its position in shares of Genomic Health by 269.5% during the third quarter. Citadel Advisors LLC now owns 93,803 shares of the medical research company’s stock worth $3,010,000 after acquiring an additional 68,418 shares during the last quarter. Finally, Cowen Prime Services LLC grew its position in shares of Genomic Health by 324.1% during the second quarter. Cowen Prime Services LLC now owns 88,635 shares of the medical research company’s stock worth $2,885,000 after acquiring an additional 67,735 shares during the last quarter. Institutional investors and hedge funds own 89.61% of the company’s stock.

A number of analysts have weighed in on the stock. William Blair cut shares of Genomic Health from an “outperform” rating to a “market perform” rating in a report on Wednesday. BidaskClub raised shares of Genomic Health from a “sell” rating to a “hold” rating in a report on Tuesday. ValuEngine raised shares of Genomic Health from a “sell” rating to a “hold” rating in a report on Friday, December 15th. J P Morgan Chase & Co lowered shares of Genomic Health from a “neutral” rating to an “underweight” rating and set a $25.00 target price on the stock. in a research report on Wednesday, December 13th. Finally, Canaccord Genuity restated a “buy” rating and set a $39.00 target price on shares of Genomic Health in a research report on Wednesday, November 15th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $31.57.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Genomic Health, Inc. (GHDX) CEO Sells $630,000.00 in Stock” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/21/insider-selling-genomic-health-inc-ghdx-ceo-sells-630000-00-in-stock.html.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.